Analysts Set MiMedx Group, Inc. (MDXG) Price Target at $12.67

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have earned a consensus recommendation of “Hold” from the eight analysts that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $12.67.

Several equities research analysts recently commented on the company. BidaskClub raised MiMedx Group from a “hold” rating to a “buy” rating in a research report on Wednesday, January 31st. Needham & Company LLC cut MiMedx Group from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 20th. Lake Street Capital cut MiMedx Group from a “buy” rating to a “hold” rating and set a $9.00 price objective on the stock. in a research report on Friday, February 23rd. ValuEngine cut MiMedx Group from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 2nd. Finally, Craig Hallum reissued a “buy” rating on shares of MiMedx Group in a research report on Tuesday, February 27th.

A number of large investors have recently made changes to their positions in the business. Element Capital Management LLC purchased a new position in shares of MiMedx Group during the 1st quarter valued at about $309,000. The Manufacturers Life Insurance Company lifted its position in shares of MiMedx Group by 4.1% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,462,689 shares of the medical equipment provider’s stock valued at $10,195,000 after buying an additional 57,231 shares in the last quarter. A.R.T. Advisors LLC lifted its position in shares of MiMedx Group by 333.8% during the 1st quarter. A.R.T. Advisors LLC now owns 217,523 shares of the medical equipment provider’s stock valued at $1,516,000 after buying an additional 167,376 shares in the last quarter. UBS Group AG lifted its position in shares of MiMedx Group by 681.0% during the 1st quarter. UBS Group AG now owns 758,711 shares of the medical equipment provider’s stock valued at $5,288,000 after buying an additional 661,559 shares in the last quarter. Finally, Senzar Asset Management LLC lifted its position in shares of MiMedx Group by 24.2% during the 1st quarter. Senzar Asset Management LLC now owns 902,100 shares of the medical equipment provider’s stock valued at $6,288,000 after buying an additional 175,800 shares in the last quarter. 79.28% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group opened at $7.00 on Friday, MarketBeat reports. MiMedx Group has a one year low of $6.86 and a one year high of $7.08. The firm has a market cap of $777.24 million, a P/E ratio of 33.33, a price-to-earnings-growth ratio of 0.91 and a beta of 1.54.

MiMedx Group Company Profile

MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.

Analyst Recommendations for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply